Actinium Pharmaceuticals (ATNM) Common Equity (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Common Equity of $2.3 million for Q1 2026, down 91.03% year-over-year from $25.7 million in Q1 2025, and down 70.59% quarter-over-quarter from $7.8 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Common Equity (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Common Equity for 17 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 91.03% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 91.03% YoY), while the FY2025 annual figure was $7.8 million, down 76.09% from the prior year.
- Common Equity fell to $2.3 million in Q1 2026 per ATNM's latest filing, from $7.8 million in the prior quarter.
- Across five years, Common Equity topped out at $78.2 million in Q2 2022 and bottomed at $2.3 million in Q1 2026.
- Historically, Common Equity has averaged $41.3 million across 5 years, with a median of $43.6 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity dropped 2.68% — and 2026, when it sank 91.03%.
- Actinium Pharmaceuticals' Common Equity stood at $66.5 million in 2022, then slumped by 45.28% to $36.4 million in 2023, then retreated by 9.95% to $32.8 million in 2024, then tumbled by 76.09% to $7.8 million in 2025, then plunged by 70.59% to $2.3 million in 2026.
- Business Quant data shows ATNM's Common Equity at $2.3 million in Q1 2026, $7.8 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 30.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 7.83 Mn |
| Sep 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 19.01 Mn |
| Mar 31, 2025 | 25.69 Mn |
| Dec 31, 2024 | 32.76 Mn |
| Sep 30, 2024 | 38.21 Mn |
| Jun 30, 2024 | 43.84 Mn |
| Mar 31, 2024 | 43.86 Mn |
| Dec 31, 2023 | 36.38 Mn |
| Sep 30, 2023 | 43.58 Mn |
| Jun 30, 2023 | 53.08 Mn |
| Mar 31, 2023 | 57.21 Mn |
| Dec 31, 2022 | 66.48 Mn |
| Sep 30, 2022 | 71.26 Mn |
| Jun 30, 2022 | 78.18 Mn |
| Mar 31, 2022 | 68.84 Mn |
| Dec 31, 2021 | 73.55 Mn |
| Sep 30, 2021 | 80.29 Mn |